Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03-Reference-Cited by-同舟云学术

Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03

Published:2023-01-28 Issue:7 Volume:25 Page:2090-2098
ISSN:1699-3055
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Garcia-Donas Jesus^ORCID,Hurtado Alicia,Garrigos Laia,Santaballa Ana,Redondo Andres,Vidal Laura,Lainez Nuria,Guerra Eva,Rodriguez Victor,Cueva Juan,Bover Isabel,Palacio Isabel,Rubio Maria Jesus,Prieto Mario,Lopez-Guerrero Jose Antonio,Rodriguez-Moreno Juan Francisco,Garcia-Casado Zaida,Garcia-Martinez Elena,Taus Alvaro,de Castro Ignacio Pérez,Navarro Paloma,Grande Enrique,

Funder

Ministerio de Sanidad, Consumo y Bienestar Social

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12094-023-03085-w.pdf

Reference27 articles.

1. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol. 2003;21:1180–9.

2. Mangili G, Ottolina J, Gadducci A, Giorda G, Breda E, Savarese A, et al. Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary. Br J Cancer. 2013;109:29–34.

3. Cheung A, Shah S, Parker J, Soor P, Limbu A, Sheriff M, et al. Non-epithelial ovarian cancers: how much do we really know? Int J Environ Res Public Health. 2022;19(3):1106.

4. Ray-Coquard I, Harter P, Lorusso D, Dalban C, Vergote I, iFujiwara K, et al. Effect of weekly paclitaxel with or without bevacizumab on progression-free rate among patients with relapsed ovarian sex cord-stromal tumors: the ALIENOR/ENGOT-ov7 randomized clinical trial. JAMA Oncol. 2020;6(12):1923–30.

5. Homesley HD, Bundy BN, Hurteau JA, Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a gynecologic oncology group study. Gynecol Oncol. 1999;72(2):131–7.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti-tumoral compounds;2024-07-03

2. Clinicopathologic Characteristics of a Single-institution Cohort of Ovarian Adult Granulosa Cell Tumors, With Biomarker and Therapeutic Implications Utilizing the Detection of Androgen, Estrogen, and Progesterone Hormone Receptor Expression by Immunohistochemistry;International Journal of Gynecological Pathology;2024-03-27